Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin LymphomaRecruiting
NCT06392477Phase 1Updated Dec 23, 2025
Sponsor: Sanofi
B-cell Non Hodgkin Lymphoma
Australia, Serbia, Singapore, South Korea, Taiwan
Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world ConditionsRecruiting
NCT07052396N/AUpdated Dec 22, 2025
Sponsor: Sanofi
Chronic Obstructive Pulmonary Disease (COPD)
Germany
Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)Completed
NCT04684524Phase 3Updated Dec 22, 2025
Sponsor: Sanofi
Allergic Fungal Rhinosinusitis
United States, Argentina, Canada, China, India +4 more
REAnimation Low Immune Status MarkersCompleted
NCT02638779NAUpdated Dec 19, 2025
Sponsor: Hospices Civils de Lyon
Septic Shock · Severe Trauma · Severe Burn · Major Surgery
France
Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo NodularisRecruiting
NCT07276425N/AUpdated Dec 18, 2025
Sponsor: UMC Utrecht
Prurigo Nodularis (PN)
Netherlands
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IXActive Not Recruiting
NCT03754790Phase 3Updated Dec 17, 2025
Sponsor: Genzyme, a Sanofi Company
Hemophilia
United States, Australia, Canada, China, Denmark +15 more
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)Terminated
NCT04009681Phase 1, Phase 2Updated Dec 15, 2025
Sponsor: Synthorx, Inc, a Sanofi company
Metastasis
United States, Argentina, Australia, Chile, Singapore +1 more
Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.Not Yet Recruiting
NCT06694025N/AUpdated Dec 15, 2025
Sponsor: Sanofi
Immunization · Influenza (Healthy Volunteers)
South Korea
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple MyelomaActive Not Recruiting
NCT04270409Phase 3Updated Dec 12, 2025
Sponsor: Sanofi
Plasma Cell Myeloma
United States, Australia, Brazil, Canada, China +19 more
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and OlderActive Not Recruiting
NCT06686654Phase 1, Phase 2Updated Dec 11, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Human Metapneumovirus Immunization · Respiratory Syncytial Virus Immunization
United States
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic DermatitisTerminated
NCT06058156Phase 2Updated Dec 11, 2025
Sponsor: Sanofi
Atopic Dermatitis
United States, Czechia, Germany, Greece, Poland +1 more
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaTerminated
NCT06028230Phase 2Updated Dec 11, 2025
Sponsor: Sanofi
Hidradenitis Suppurativa
United States, Canada, Chile, Germany, Greece +3 more
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)Active Not Recruiting
NCT04598893N/AUpdated Dec 9, 2025
Sponsor: Provention Bio, a Sanofi Company
Diabetes Mellitus, Type 1
United States, Belgium, Canada, Czechia, France +3 more
A Study to Evaluate the Quality of Life in Male and Female Adult Participants With Severe Asthma Treated With Dupilumab in a Real-world SettingCompleted
NCT06018441N/AUpdated Dec 9, 2025
Sponsor: Sanofi
Asthma
France
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal MelanomaRecruiting
NCT06121180Phase 2Updated Dec 4, 2025
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Metastatic Uveal Melanoma
United States
A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United StatesRecruiting
NCT07260110N/AUpdated Dec 3, 2025
Sponsor: Sanofi
Type 1 Diabetes
United States
A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of KoreaRecruiting
NCT07200206N/AUpdated Dec 3, 2025
Sponsor: Sanofi
Respiratory Syncytial Virus
South Korea
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of AgeCompleted
NCT06641180Phase 3Updated Dec 3, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
United States
Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and ToddlersCompleted
NCT06284915Phase 3Updated Dec 2, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation · Healthy Volunteers
Czechia, Denmark, Finland, Germany, Poland +1 more
Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)Recruiting
NCT04843111N/AUpdated Dec 1, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Infection
United States
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's DiseaseCompleted
NCT03439943Phase 2Updated Nov 28, 2025
Sponsor: University Hospital, Toulouse
Parkinson Disease
France
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple MyelomaRecruiting
NCT06517017Phase 2Updated Nov 28, 2025
Sponsor: University of Utah
Multiple Myeloma · Plasma Cell Leukemia
United States
Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With DupilumabWithdrawn
NCT07187089Phase 4Updated Nov 28, 2025
Sponsor: Regeneron Pharmaceuticals
Severe Atopic Dermatitis (AD)
Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of AgeCompleted
NCT06582056NAUpdated Nov 28, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Periodontal Disease
United States
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)Active Not Recruiting
NCT02570542Phase 2Updated Nov 26, 2025
Sponsor: Memorial Sloan Kettering Cancer Center
Diffuse Large B-cell Lymphoma (DLBCL) · Relapsed Diffuse Large B-cell Lymphoma (DLBCL) · Refractory Diffuse Large B-cell Lymphoma (DLBCL)
United States

Previous page Next page